IPP Bureau
Alvotech and Teva get US FDA approval of Selarsdi
By IPP Bureau - April 17, 2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Positive data for Roche multiple sclerosis injection
By IPP Bureau - April 17, 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Cipla Health strengthens its play in beauty and personal care
By IPP Bureau - April 16, 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
Ami Organics accredited Gold Medal by EcoVadis
By IPP Bureau - April 16, 2024
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Moderna pauses plan to build mRNA manufacturing facility in Kenya
By IPP Bureau - April 16, 2024
The demand in Africa for COVID-19 vaccines has declined
Novartis reports data from trial of IgA nephropathy treatment
By IPP Bureau - April 16, 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
By IPP Bureau - April 16, 2024
Global Phase-3 study initiation expected in the second half of 2024
Laurus Labs forms JV company
By IPP Bureau - April 16, 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
Croda and AAHI partner to drive innovation in vaccine development
By IPP Bureau - April 15, 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Teva confirms efficacy and safety of Ajovy for prevention of migraine
By IPP Bureau - April 15, 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Novartis tender offer for MorphoSys commences
By IPP Bureau - April 15, 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
.jpg "Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations")
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
By IPP Bureau - April 14, 2024
This facility manufactures APIs & formulations of oncology and non-oncology products.
Briefs: Sun Pharma and Kimia Biosciences
By IPP Bureau - April 14, 2024
Sun Pharma's Dadra facility receives OAI status from US FDA
Merck India appoints Dhananjay Singh as MD Merck Life Science in India
By IPP Bureau - April 13, 2024
USFDA completes inspection of Lupin's Dabhasa facility with no observations
By IPP Bureau - April 13, 2024
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
